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ABSTRACT
Background: Allergen avoidance is important in allergic asthma management. Nocturnal treat-
ment with Temperature-controlled Laminar Airflow (TLA) has been shown to provide a significant 
reduction in the exposure to allergens in the breathing zone, leading to a long-term reduction in 
airway inflammation and improvement in Quality of life (QoL). Allergic asthma patients sympto-
matic on Global Initiative for Asthma (GINA) step 4/5 were found to benefit the most as measured 
by Asthma Quality of Life Questionnaire (AQLQ). However, the effect of TLA on severe asthma 
exacerbations is uncertain and therefore a meta-analysis was performed.
Methods: Patients with severe allergic asthma (GINA 4/5) were extracted from two 1-year 
randomised, double-blind, placebo-controlled trials conducted with TLA. A meta-analysis of the 
effect on severe exacerbations was performed by negative binomial regression in a sequential 
manner, defined by baseline markers of asthma control (symptoms and QoL scores).
Results: The pooled dataset included 364patients. Patients with more symptoms at baseline 
(ACT<18 or ACQ7>3; N=179), had a significant mean 41% reduction in severe exacerbations 
(RR=0.59 (0.38-0.90); p=0.015) in favour of TLA. Higher ACQ7 cut-points of 3.5-4.5 resulted in 
significant reductions of 48-59%.More uncontrolled patients based on AQLQ total and symptom 
domains ≤3.0 at baseline also showed a significant reduction in severe exacerbations for TLA vs. 
placebo ((47% (p=0.037) and 53% (p=0.011), respectively). The meta-analysis also confirmed a 
significant difference in AQLQ-responders ((Minimal Clinically Important Difference)≥0.5; 74% vs. 
43%, p=0.04).
Conclusion: This meta-analysis of individual patient data shows a beneficial effect on severe 
exacerbations and quality of life for TLA over placebo in more symptomatic patients with severe 
allergic asthma. These outcomes support the national management recommendations for 
patients with symptomatic severe allergic asthma. The actual effect of TLA on severe exacerba-
tions should be confirmed in a prospective study with larger numbers of patients.
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Introduction
Treatment alternatives for patients with symptomatic 
severe asthma include high-dose inhaled corticoster-
oids (ICS) plus a bronchodilator (e.g. long-acting 
β2-agonists and/or muscarinic antagonists) and leuko-
triene receptor antagonists according to Global 
Initiative for Asthma (GINA) step 4/5 [1]. 
Alternatives for add-on treatment for such patients 
include systemic corticosteroids, anti-immunoglobulin 
E treatments and monoclonal antibody inhibitors of 
interleukins 4, 5, and 13 [2–4]. All treatment alterna-
tives are effective, with long-term safety favouring the 
biological agents, though post-market experience dif-
fers, and the costs of biological treatments are very high 
[5,6]. A concurrent treatment option for severe asthma 
which has received little attention is allergen avoidance. 
One such method involves nocturnal temperature- 
controlled laminar airflow (TLA). TLA reduces expo-
sure to allergens and irritant particles during sleep by 
delivering filtered and slightly cooled air to the breath-
ing zone of the patient [7,8]. A double-blind, placebo- 
controlled one-year trial in patients with inadequately 
controlled persistent allergen-driven asthma by Boyle 
et al. (the 4A asthma trial) [9] demonstrated 
a significant difference in Asthma Quality of Life 
Questionnaire (AQLQ) responder rate for TLA com-
pared to placebo. The effect of TLA increased in the 
pre-defined subgroups with more symptomatic and 
severe asthma [9,10]. In an open-label study, TLA 
was shown to reduce severe exacerbations [11]. 
Reductions in airway inflammation by TLA as shown 
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by reductions in exhaled nitric oxide levels (FeNO) 
have also been reported [9,12]. TLA has shown cost- 
effectiveness at ranges consistent with the National 
Institute for Health and Care Excellence (NICE) stan-
dards [8,13]. These data have led to TLA being recom-
mended for asthma patients with symptomatic severe 
allergic asthma as stated by NICE, the Scottish, and the 
Swedish guidelines [14,15].
In the 4A asthma trial, which was not powered to 
investigate an effect on exacerbations, no effect could 
be demonstrated on severe exacerbations, when all 
patients were included (annual exacerbation rate: 
0.17 for TLA vs 0.24 for placebo; rate ratio 
(RR) = 0.71; p = 0.5) [7]. However, in the pre- 
defined subgroups, increased reduction in exacerba-
tion rates was observed when more symptomatic and 
more severe patients were analyzed separately. For 
patients with symptomatic severe asthma defined as 
GINA 4/5 and Asthma Control Test (ACT)<18 
(n = 87), a 59% reduction of severe exacerbations 
was demonstrated (annual exacerbation rate: 0.23 for 
TLA vs 0.57 for placebo; RR = 0.41; p = 0.07) [7,9]. 
Recently, a one-year study (LASER) by Kapoor et al. 
[16] in patients treated according to GINA step 4/5 
showed no significant effect on severe exacerbations 
(RR = 0.92; p = 0.62) between TLA and placebo. The 
study demonstrated a high placebo response, espe-
cially in the patients with better symptom control, 
while the difference in effect between TLA and pla-
cebo descriptively increased for patients with more 
symptoms.
Our main objective was to investigate the effect of 
TLA on severe exacerbations among patients with 
more symptomatic severe allergic asthma when the 
two 1-year studies were pooled into a dataset for 
a meta-analysis of individual patient data. ACQ + 
ACT, symptom domain of AQLQ and total AQLQ 
were used as baseline cut-offs to extract exacerbation- 
prone patients. The secondary objective was to confirm 
the effect on the responder rate ratio for AQLQ, as 
demonstrated in the 4A asthma trial [9].
Materials and methods
The current study is a post-hoc analysis of data from 
the LASER trial (Kapoor et al., ClinicalTrials.gov 
NCT02813811) [16] and the 4A asthma trial (Boyle 
et al., ClinicalTrials.gov NCT00986323) [9]. In the fol-
lowing text, the LASER trial will be referred to as Study 
A and the full 4A asthma trial as Study B1. The subset 
of patients with symptomatic severe allergic asthma 
(i.e. only GINA 4/5) from the 4A asthma trial will be 
referred to as Study B2.
Ethics
Kapoor et al.: The study was approved by Health 
Research Authority: NRES Committee South 
Central – Berkshire REC Reference 14/SC/0092, IRAS 
Project ID 148,386, and written informed consent was 
obtained from all patients. Boyle et al.: The study was 
approved by responsible institutional review boards in 
each participating centre and written informed consent 
was obtained from all patients/parents. The studies 
complied with the Declaration of Helsinki.
Patients
In Study A, patients with a clinical diagnosis of asthma 
were aged 16–75 years, treated according to GINA 4/5, 
severe asthma defined by requirement for high-dose ICS 
plus a second controller and/or systemic corticosteroids, 
poorly controlled asthma demonstrated by two or more 
severe asthma exacerbations, requiring systemic corticos-
teroids in the preceding 12 months plus an Asthma 
Control Questionnaire (ACQ)7 score >1, and atopic status, 
defined as sensitisation to ≥1 perennial indoor aeroaller-
gens [16]. In Study B1, patients with physician-diagnosed 
asthma were aged 7–70 years, with asthma treated accord-
ing to GINA 2–4/5, defined by daily use of inhaled corti-
costeroids (ICS) for the last 6 months, poorly controlled 
asthma demonstrated by AQLQ-score ≤5.5 at inclusion, 
and atopic status, defined by sensitisation to a pet allergen 
(cat and/or dog) and/or house dust mite.
In the current study (Study A+ B2), a pooled dataset 
with individual patient data from the two studies is pre-
sented (Figure 1), including all patients with severe allergic 
asthma treated according to GINA step 4/5 from both 
studies.
Study design
The original studies, Study A and Study B1 [9,16] were 
both phase III multicentre, double-blind, placebo- 
controlled, parallel-group trials in which patients were 
randomised to receive add-on treatment with TLA 
(Airsonett AIR4, Airsonett AB, Ängelholm; Sweden) 
or a placebo device for 1 year. In Study A and B1 all 
participants were evaluated during the study at baseline 
and after 3, 6, 9, and 12 months, and via completion of 
a diary. The randomization ratio was 1:1 in Study 
A and 2 (TLA):1 (placebo) in Study B1.
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Preparation of the pooled dataset
The final analysis datasets from Study A and Study B1 
were retrieved. Patients from Study B1 not in GINA 4/ 
5 were removed. Baseline demography, lung function, 
ACQ7 (from study A), ACT (from study B2), AQLQ- 
scores, and severe exacerbations were extracted into the 
pooled dataset, as they were collected and data-locked 
in the respective study. Both studies defined severe 
exacerbations in accordance with the American 
Thoracic Society/European Respiratory Society (ATS/ 
ERS) guidelines [17]. For further details regarding the 
collection of severe exacerbations, see the papers by 
Boyle et al. [9] and Kapoor et al. [16].
Outcome measures
In Study A, the primary outcome was the frequency of 
severe asthma exacerbations occurring over a 12- 
month period. In Study B1 the primary outcome mea-
sure was the response rate in QoL assessed by Mini 
AQLQ or in children 7–11 years, the Paediatric AQLQ 
(PAQLQ), and in the following text, the term AQLQ 
has been used in the combined mini-AQLQ and 
PAQLQ dataset. Severe exacerbations were recorded 
as a secondary outcome. In addition, three pre- 
specified sub-groups were also analysed: ACT score 
<18; GINA 4/5; ACT score <18 plus GINA 4/5.
In the current study, the primary objective was to 
assess whether TLA is effective in reducing severe 
exacerbations in patients with more symptomatic 
severe allergic asthma. The primary outcome on severe 
exacerbations in symptomatic patients was performed 
using baseline ACQ in Study A and baseline ACT in 
Study B1 as cut points, due to the use of different 
symptom questionnaires in the two studies. The two 
baseline symptom questionnaires were used separately 
(not combined) per study to extract exacerbation- 
prone patients. This analysis was complemented by 
using the baseline symptom domain in AQLQ and 
baseline total AQLQ, using total AQLQ as the cut 
point. The secondary objective was to confirm the 
effect on the responder rate ratio for total AQLQ, 
using baseline total AQLQ as cut point, as demon-
strated in Study B1.
Statistical analyses
The data were summarised and analysed by similar 
methods as previously used for the two studies, 
a negative binomial regression for the number of severe 
exacerbations, and logistic regression of responders for 
Figure 1. Flow chart over the study population.
Abbreviations: GINA, Global Initiative for Asthma; ITT, Intention To Treat; n, number of patients; TLA, Temperature-controlled Laminar Airflow; PLA, 
placebo. 
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AQLQ. For the meta-analysis of individual patient 
data, treatment and study were fixed factors. With 
study as a fixed factor in the model, the pooled results 
are approximately weighted by study size. Baseline 
AQLQ was used as a covariate when analysing 
AQLQ. No covariates were used for the analysis 
of number of severe exacerbations.
To describe the data across the range of the baseline 
values a cumulative approach was used where data 
were averaged stepwise up to each of the ordered 
unique values of the particular baseline variable. 
A significant effect on the number of severe exacerba-
tions was determined using sequential analysis with 
baseline scores increasing or decreasing with 0.5 unit 
scores until no significant difference could be 
demonstrated.
ACQ was reduced as described above, while 
ACT<18 was used as a fixed cut- 
point because this symptom severity cut-point was pre- 
specified in Study B1. Evidence has been identified for 
a relationship between ACT score and ACQ score [18], 
and both scores have been shown to correctly predict 
GINA-defined uncontrolled asthma [19]. Due to low 
patient numbers, the data were not analysed at the 
extreme of severity. In this post-hoc analysis statistical 
significance level was 5% (two-sided) and no overall 
adjustment for multiple testing was employed.
Results
Patient populations
The population for the primary analysis in Study A and 
Study B1 included 240 and 282 patients, respectively. 
For further details and patient flow in the respective 
study, see [9] and [16].
Table 1 presents baseline demographics for the 
population extracted in the current study. From study 
A, all patients for whom data on AQLQ were available 
were included (N = 235). From study B2 all patients in 
GINA 4/5 were included (N = 129) (Figure 1). The 
pooled dataset from Study A and Study B2 thus 
included 364 patients. Within each of the studies, the 
TLA and placebo treatment groups had similar baseline 
demographic and clinical characteristics, but Study 
A included older and more obese patients, a higher 
number of female patients, and patients with lower 
lung function than Study B2.
Asthma exacerbations
Neither Study A nor Study B2 separately showed 
a statistically significant difference between TLA and 
placebo for severe asthma exacerbations. Figure 2 gives 
a descriptive presentation of the rate of severe asthma 
exacerbations over 12 months for TLA and placebo in the 
individual studies by baseline ACQ7 (Study A, Figure 2 
(a)) and ACT (Study B2, Figure 2(b)). In both studies, the 
rate difference between TLA and placebo consistently 
increased with lower symptom control at baseline.
Table 2 presents the pooled results for Study A+ B2 
by different cut-points for baseline ACQ7/ACT. 
A significant reduction of severe exacerbations was 
shown in favour of TLA over placebo across the 
range (59%, 51%, 48%, 41%, respectively). A cut-point 
of ACQ7 = 2.5 and ACT = 18 resulted in a non- 
significant 27% reduction (p = 0.096). A sensitivity 
analysis in patients aged 16 upwards was performed, 
Table 1. Characteristics of study patients at baseline in the individual studies and the pooled dataset.
Study A Study B2a Study A+ B2
TLA 
(n = 115) Placebo (n = 120)
TLA 
(n = 82) Placebo (n = 47)
TLA 
(n = 197) Placebo (n = 167)
Age (years) 46.8 (13.8) 45.3 (13.8) 27.1 (15.2) 26.9 (16.6) 38.6 (14.3) 40.1 (14.6)
Age ≤12, n (%) 0 0 18 (22.0) 14 (29.8) 18 (9.1) 14 (8.4)
Male sex, n (%) 33 (28.7) 30 (25.0) 46 (56.1) 24 (51.1) 79 (40.1) 54 (32.3)
Race, n (%)
Caucasian 100 (87.0) 103 (85.8) 64 (78.0) 40 (85.1) 164 (83.2) 143 (85.6)
Black 2 (1.7) 2 (1.7) 6 (7.3) 1 (2.1) 8 (4.1) 3 (1.8)
Oriental 8 (7.0) 11 (9.2) 3 (3.7) 1 (2.1) 11 (5.6) 12/7.2)
Other 5 (4.3) 4 (3.3) 9 (11.0) 5 (10.6) 14 (7.1) 9 (5.4)
BMI (kg/m2) 29.6 (5.9) 31.2 (7.2) 23.2 (4.8) 23.2 (5.8) 26.9 (6.3) 28.9 (7.7)
FEV1 (L) 2.09 (0.86) 2.02 (0.81) 2.69 (0.89) 2.71 (0.78) 2.34 (0.87) 2.21 (0.80)
FEV1 (% predicted)
b 69.7 (22.6) 69.0 (21.0) 87.3 (17.6) 88.6 (15.6) – – - – – -
AQLQ 4.09 (1.21) 3.89 (1.23) 4.14 (0.91) 4.14 (1.08) 4.11 (1.09) 3.96 (1.19)
ACT – – - – – - 15.7 (3.4) 15.9 (3.9) – – - – – -
ACQ7 2.84 (1.00) 3.05 (1.08) – – - – – - – – - – – -
Abbreviations: GINA, Global Initiative for Asthma; TLA, Temperature-controlled Laminar Airflow; PLA, placebo; BMI, Body Mass Index; FEV1, forced expiratory 
volume in 1 second; ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire 
Notes: Values are mean (SD) unless otherwise specified. n TLA/PLA is the number of patients in the subgroup; a Randomisation in Study B2: TLA-Placebo 2:1; 
b Study A: Pre-bronchodilator; Study B2: Post-bronchodilator. 
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as Study A contrary to Study B2 included no children. 
No important differences were found.
Figure 3 presents the pooled results for Study A+ B2 
by different cut-off points for baseline AQLQ. For 
more symptomatic patients with severe asthma defined 
as AQLQ symptom domain ≤3.0, a significant 53% 
reduction of severe exacerbations (p = 0.011) was 
observed for TLA over placebo in the pooled dataset. 
For patients with AQLQ total ≤3.0 at baseline, the 
reduction of severe asthma exacerbations for TLA vs 
placebo was 47% (p = 0.037).
Quality of life
Using baseline AQLQ as a covariate, Figure 4 presents 
the proportion of responders (Minimal Clinically 
Important Difference (MCID) ≥0.5) [9] in AQLQ 
after 12 months for TLA and placebo in the pooled 
dataset. A significant difference in the number of 
responders between TLA and placebo was observed 
for patients with baseline AQLQ ≤ 3.0 (74% vs. 43%, 
p = 0.04). The stopping criterium for non-significance 
was reached at AQLQ total = 3.5 (71% vs.55%; 
p = 0.11).
Discussion
This post-hoc meta-analysis of two double-blind 
12 month’s studies investigated the effect of TLA and 
placebo in patients with severe allergic asthma. TLA 
showed significant effects in more symptomatic 
patients on severe exacerbations (41–59% reduction) 
and AQLQ response (74% vs.43%) compared to 
placebo.
Figure 2. Descriptive presentation of the rate of severe asthma exacerbations over 12 months in Study A and Study B2 by baseline 
ACQ7 and ACT-scores for TLA-treated (solid line) and placebo-treated (dotted line) patients. (a): Baseline ACQ7 score in Study A. (b): 
Baseline ACT score in Study B2.
Abbreviations: ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; TLA, Temperature-controlled Laminar Airflow; PLA, placebo. Notes: 
Dashed vertical line represents ACT = 18, the prespecified cut-off in Study B2. 
Table 2. Rate ratios for severe asthma exacerbations in the pooled dataset for different cut-off levels of baseline ACQ7/ACT scores, 
total AQLQ score, and AQLQ symptom domain score.
TLA (n) TLA (nex) Rate TLA PLA (n) PLA (nex) Rate PLA RR (95% CI) p-value
ACQ7/ACT interval
>4.5 and <18 62 19 0.31 42 50 1.19 0.41 (0.18–0.94) 0.036
>4.0 and <18 71 31 0.44 55 78 1.42 0.46 (0.24–0.86) 0.016
>3.5 and <18 83 48 0.58 67 100 1.49 0.52 (0.31–0.86) 0.012
>3.0 and <18 100 75 0.75 79 122 1.54 0.59 (0.38–0.90) 0.015
>2.5 and <18 118 106 0.90 102 147 1.44 0.73 (0.50–1.06) 0.096
AQLQ interval
Total AQLQ score
≤ 2.5 20 11 0.55 19 41 2.16 0.33 (0.13–0.71) 0.014
≤ 3.0 33 31 0.94 32 68 2.13 0.53 (0.29–0.70) 0.037
≤ 3.5 51 49 0.96 55 92 1.67 0.63 (0.37–0.72) 0.083
AQLQ symptoms domain only
≤ 2.5 17 12 0.71 30 71 2.37 0.37 (0.16–0.79) 0.011
≤ 3.0 42 37 0.88 46 94 2.04 0.47 (0.26–0.84) 0.011
≤ 3.5 66 67 1.02 62 102 1.65 0.70 (0.43–1.12) 0.132
Abbreviations: TLA, Temperature-controlled Laminar Airflow; PLA, placebo; RR, Rate ratio; ACQ, Asthma Control Questionnaire; ACT, Asthma Control Test; 
AQLQ, Asthma Quality of Life Questionnaire 
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These results diverge from the full LASER trial [16], 
which showed small and non-significant differences for 
severe exacerbations (8% reduction) and modest effects 
on AQLQ. In the 4A asthma trial [9] there was an 
overall significant difference between TLA and placebo 
on AQLQ responder rate, and a non-significant effect 
on severe exacerbations in the sub-group of patients 
with symptomatic severe allergic asthma (GINA 4/5 
+ ACT< 18). Therefore, this meta-analysis investigating 
the effect of TLA on severe exacerbations was initiated, 
as the two studies had low power for analysis of severe 
exacerbations in the more symptomatic severe allergic 
asthma patient population and since all sub-analyses 
further lowered the number of patients to be included. 
Descriptively, there was a broad difference in severe 
exacerbations between TLA and placebo in more 
symptomatic patients – a greater effect difference as 
severity increased. The more symptomatic patients 
Figure 3. Rate of severe asthma exacerbations over 12 months in the pooled dataset by different cut-off points for baseline total 
AQLQ for TLA-treated (solid line) and placebo-treated (dotted line) patients. (a): total AQLQ score. (b): AQLQ symptom domain only.
Abbreviations: AQLQ, Asthma Quality of Life Questionnaire; TLA, Temperature-controlled Laminar Airflow; PLA, placebo. Notes: * denotes a p-value 
<0.05 for the rate ratio. 
Figure 4. Proportion of responders in AQLQ after 12 months in the pooled dataset by different cut-off points for baseline total 
AQLQ for TLA (solid line) and placebo (dotted line).
Abbreviations: AQLQ, Asthma Quality of Life Questionnaire; TLA, Temperature-controlled Laminar Airflow; PLA, placebo. Notes: * denotes a p-value 
<0.05 for the difference in the number of responders. 
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showed a significant reduction in severe exacerbations 
in favour of TLA, both for validated questionnaires 
(ACQ7 and ACT) and the AQLQ symptom domain.
The effect on severe exacerbation of around 50% for 
TLA compared to placebo in the more symptomatic 
patients demonstrated in this pooled analysis is of 
similar magnitude to the effect demonstrated by biolo-
gical agents [2–4]. One further possible explanation for 
the larger treatment response among the more severe 
allergic asthma patients is the association between 
allergy and asthma. With increased allergen load the 
disease becomes more severe, i.e. more difficult to 
control [20].
Another important topic is whether patients who are 
sensitized to more allergens respond better to TLA 
than those less sensitized. The data from the two stu-
dies were not suitable for pooling. In a post-hoc ana-
lysis of the Boyle study, it has been reported that 
patients with ACT score <18 plus GINA 4/5 plus 
allergic response to 2 or more allergens had 
a significant reduction in the number of severe exacer-
bations for TLA compared to placebo (p = 0.02; 
n = 61). In the same subgroup, but with an allergic 
response to one or more allergens, the result was not 
significant (p = 0.07; n = 87) [7]. The significance in 
the more sensitized group may indicate that multi- 
sensitization has impact on the outcome
The importance of poor control and the future risk 
of severe exacerbations in asthma has been demon-
strated in a number of studies, using asthma control 
questionnaires, such as ACT and ACQ as a surrogate, 
quantitative estimates of control [21–23]. Within these 
measures, the presence and severity of symptoms in 
predicting exacerbations are important, and they 
remain the second most common predictor (after 
a history of previous exacerbations) of future risk. 
The evidence for asthma control is therefore strong 
while questionnaires on asthma QoL focusing on 
symptom and non-symptom domains are less consis-
tent in predicting future risk of exacerbation [23]. It 
has also been shown that shorter disease questionnaires 
(Airways Questionnaire 20 (AQ20) and COPD Control 
Questionnaire (CCQ)) focusing on symptoms are more 
predictive than broader, more time-consuming disease 
questionnaires (such as AQLQ and St. George’s 
Respiratory Questionnaire (SGRQ)) in the prediction 
of exacerbations and hospitalisations [24]. It is, there-
fore, logical to use an easily administered control ques-
tionnaire (e.g. ACQ) as an inclusion criterion in studies 
where severe exacerbations are the primary outcome, 
as used in the LASER study (ACQ7 > 1) and in the 
biological study programmes (ACQ6 > 1.5). In our 
analyses of the TLA effect on severe exacerbations, we 
demonstrated increasing reductions in exacerbations 
using cut-off points for asthma control (ACQ and 
ACT) as well as AQLQ (especially when using the 
symptoms domain of AQLQ). However, more patients 
were included in the pooled analyses if control ques-
tionnaires (ACQ7+ ACT) were used than if a QoL 
instrument was used (AQLQ total). This may indicate 
that validated symptom control questionnaires are bet-
ter and more easily define the right patient population 
for predicting a positive TLA response to severe 
exacerbations.
Descriptively, the proportion of responders on TLA 
was around 70% for most baseline AQLQ scores. 
However, the proportion of placebo responders was 
low in patients with the most symptomatic severe 
allergic asthma (30–40%). A baseline AQLQ-value of 
>3.0 resulted in a placebo response rate of around 60% 
(see Figure 4), indicating a prominent placebo response 
in patients with milder symptoms, which may have 
lowered the possibility for TLA to show significant 
effects over placebo.
Allergen avoidance using air purifications could be 
an alternative to TLA. However, the effectiveness in 
asthma treatment by conventional air purification is 
limited and a recently published meta-analysis by 
Boven et al. [25] showed that the only significant 
clinical results (AQLQ and FeNO) were demonstrated 
with TLA. A plausible explanation has been given by 
Spilak et al. [26], who demonstrated that TLA signifi-
cantly reduces the intrusion of airborne particles into 
the breathing zone with particle number concentra-
tions being 100-fold lower compared to air-cleaners, 
which attempt to reduce the allergen/particle load in 
the whole room, rather than focused in the breathing 
zone.
The post-hoc nature of the analysis is a limitation in 
itself, and many analyses have been performed on 
a relatively small dataset. The analyses are exploratory 
rather than pre-specified in order  to find possible areas 
for further studies. However, the selected sub-groups 
were outlined already in the protocol for the 4A asthma 
trial. In that study, it was demonstrated that more 
symptomatic patients (ACT<18) and/or more severe 
patients (GINA 4/5) showed a greater effect with TLA 
compared with placebo. In the meta-analysis, multiple 
analyses were performed, but we sequenced the ana-
lyses and stopped when no significance was reached in 
order  to minimize multiplicity. It should also be noted 
that with a greater sample size for the sub-analysis, 
more information could have been obtained. A logical 
next step would be to repeat an adequately powered 
study to validate the sub-group findings. Other poten-
tial limitations are the differences in patient numbers, 
EUROPEAN CLINICAL RESPIRATORY JOURNAL 7
in patient populations and the use of two different 
baseline asthma symptom scores (ACQ and ACT) in 
the two studies, adding heterogeneity to the pooled 
dataset. As in other meta-analyses, we used a fixed 
factor in the model, i.e. the pooled results are approxi-
mately weighted by study size. In addition, a sensitivity 
analysis was performed on the 4A asthma trial, show-
ing no difference in exacerbation rate when patients 
aged 15 and younger were omitted. All data, however, 
indicated that TLA demonstrated a better add-on effect 
in the more symptomatic patients, irrespective of sever-
ity based on medication load.
In conclusion, this meta-analysis of individual 
patient data shows a beneficial effect on severe exacer-
bations and quality of life for TLA over placebo in 
more symptomatic patients with severe allergic asthma. 
These outcomes support the national management 
recommendations for patients with symptomatic severe 
allergic asthma. The actual effect of TLA on severe 
exacerbations in the recommended patient population 
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